{"id":"placebo-equivalent-to-amoxycillin","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL2105950","moleculeType":"Small molecule","molecularWeight":"387.39"},"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Placebo equivalent to amoxycillin","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T04:50:03.288780+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T04:50:20.247309+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T04:50:10.300426+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Placebo equivalent to amoxycillin","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T04:50:11.262026+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2105950/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T04:50:12.043091+00:00"}},"_dailymed":null,"aiSummary":"Placebo equivalent to amoxycillin, marketed by Menzies School of Health Research, holds a unique position in the therapeutic landscape as a non-active comparator. The key composition patent is set to expire in 2028, which may provide a period of exclusivity and stability in the market. However, the lack of a defined mechanism and primary indication poses a significant risk in terms of regulatory scrutiny and market acceptance.","mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is an inert placebo preparation manufactured to match the appearance, taste, and administration characteristics of amoxicillin (a beta-lactam antibiotic) for blinded clinical trial purposes. It contains no active pharmaceutical ingredient and therefore produces no antimicrobial effect, allowing researchers to isolate and measure placebo response in study populations.","oneSentence":"A placebo formulation designed to mimic amoxicillin for use in clinical trials or research studies without providing active antibiotic effect.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:00:41.342Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T04:50:20.247754+00:00","fieldsConflicting":0,"overallConfidence":0.95},"indications":{"approved":[{"name":"Control arm in clinical trials evaluating amoxicillin efficacy"}]},"trialDetails":[{"nctId":"NCT02783859","phase":"PHASE4","title":"Hospitalised Pneumonia With Extended Treatment (HOPE) Study","status":"COMPLETED","sponsor":"Menzies School of Health Research","startDate":"2016-06","conditions":"Pneumonia","enrollment":314},{"nctId":"NCT01980095","phase":"PHASE3","title":"ERADICATE Hp - Treating Helicobacter Pylori With RHB-105","status":"COMPLETED","sponsor":"RedHill Biopharma Limited","startDate":"2013-11","conditions":"Dyspepsia, Helicobacter Pylori Infection","enrollment":119},{"nctId":"NCT00066066","phase":"PHASE2","title":"Effect of Three Periodontal Therapies in Current Smokers and Non-Smokers","status":"COMPLETED","sponsor":"The Forsyth Institute","startDate":"2003-07","conditions":"Periodontitis, Periodontal Diseases","enrollment":146},{"nctId":"NCT01602874","phase":"PHASE3","title":"Study Evaluating Tigecycline Versus Ceftriaxone In Complicated Intra-Abdominal Infections & Community Acquired Pneumonia","status":"WITHDRAWN","sponsor":"Pfizer","startDate":"2011-01","conditions":"Community Acquired Bacterial Pneumonia, Complicated Intra-Abdominal Infection","enrollment":""},{"nctId":"NCT00914888","phase":"PHASE3","title":"Study Evaluating Tigecycline Versus Ceftriaxone In Complicated Intra-Abdominal Infections & Community Acquired Pneumonia","status":"WITHDRAWN","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2011-01","conditions":"Community Acquired Bacterial Pneumonia, Complicated Intra-Abdominal Infection","enrollment":""},{"nctId":"NCT00539149","phase":"PHASE4","title":"Long-term Antibiotics for Treatment and Prevention of Otitis Media in Aborignal Children","status":"COMPLETED","sponsor":"Menzies School of Health Research","startDate":"1996-04","conditions":"Otitis Media","enrollment":126}],"_emaApprovals":[],"_faersSignals":[],"crossReferences":{"chemblId":"CHEMBL2105950"},"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Placebo equivalent to amoxycillin","genericName":"Placebo equivalent to amoxycillin","companyName":"Menzies School of Health Research","companyId":"menzies-school-of-health-research","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T04:50:20.247754+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}